Mantle Cell Lymphoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MNT001 MIFTS: 76	Mantle Cell Lymphoma Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Mantle Cell Lymphoma

MalaCards integrated aliases for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma ³⁷ ¹² ⁷² ⁴⁹ ⁵⁵ ³⁶ ²⁸ ¹⁴

Lymphoma, Mantle Cell ⁴⁹ ¹³

Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse ⁶⁹

Malignant Lymphoma - Lymphocytic, Intermediate Differentiation ⁶⁹

Lymphoma, Mantle-Cell ⁴¹

Mantle Zone Lymphoma ⁵⁵

Lymphoma Mantle-Cell ⁵¹

Mcl ⁵⁵

Lcm ⁵⁵

Characteristics:

Orphanet epidemiological data:

⁵⁵

mantle cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (United States),1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Immune diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³³ ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Non-follicular lymphoma

Mantle cell lymphoma

Orphanet: ⁵⁵

Rare haematological diseases

External Ids:

Disease Ontology ¹² DOID:0050746

MeSH ⁴¹ D020522

Orphanet ⁵⁵ ORPHA52416

MESH via Orphanet ⁴² D020522

UMLS via Orphanet ⁷⁰ C0555202

ICD10 via Orphanet ³³ C83.1

KEGG ³⁶ H01464

ICD10 ³² C83.1

SNOMED-CT via HPO ⁶⁵ 16294009 161832001 262285001 more

UMLS ⁶⁹ C0555202 C0334634

Sources

Summaries for Mantle Cell Lymphoma

NIH Rare Diseases : ⁴⁹ Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin’s lymphomas (NHL). NHL's are cancers that affect the the lymphatic system (part of the immune system). In MCL, there are cancerous B-cells (a type of immune system cell). The cancerous B-cells are within a region of the lymph node known as the mantle zone. Although MCLs are slow-growing cancers, the cancer is usually widespread by the time it is diagnosed. In these situations, treatment must be intensive since MCL can become life threatening within a short period of time. MCL accounts for 6% of all NHL's and is mostly found in males during their early 60s. Last updated: 4/27/2016

MalaCards based summary : Mantle Cell Lymphoma, also known as lymphoma, mantle cell, is related to lymphoma and follicular lymphoma, and has symptoms including splenomegaly, weight loss and anorexia. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Imbruvica and Revlimid have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Increased cell death HMECs cells and Increased viability with MLN4924 (a NAE inhibitor)

Disease Ontology : ¹² A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

Wikipedia : ⁷² Mantle cell lymphoma (MCL) is a type of non-Hodgkin\'s lymphoma (NHL), comprising about 6% of NHL cases.... more...

Sources

Related Diseases for Mantle Cell Lymphoma

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 203)

#	Related Disease	Score	Top Affiliating Genes
1	lymphoma	32.2	ATM BCL2 BCL6 CCND1 EZH2 MYC
2	follicular lymphoma	31.9	BCL2 BCL6 CCND1 CCND3 CD5 IGH
3	composite lymphoma	30.7	BCL6 CD5 SOX11
4	prolymphocytic leukemia	30.5	ATM CCND1 CD19 CD5 MYC
5	marginal zone b-cell lymphoma	30.5	BCL2 BCL6 CCND1 CD5 MME
6	b-cell lymphomas	30.4	BCL2 BCL6 CCND1 CCND2 CCND3 CD5
7	follicular lymphoma 1	30.3	BCL2 BCL6 IGH
8	myeloma, multiple	30.3	CCND1 CCND2 CCND3 CD19 MCL1 MYC
9	retinoblastoma	30.3	CCND1 CCND3 MDM2 TP53
10	b cell prolymphocytic leukemia	30.3	CD19 CD5 MYC TP53
11	diffuse large b-cell lymphoma	30.2	BCL6 CCND1 CD5 EZH2 MDM2 MME
12	lymphoma, mucosa-associated lymphoid type	30.1	BCL2 BCL6 CCND1 CD5 IGH MME
13	lymphoblastic lymphoma	30.1	BCL6 CD5 MME
14	cll/sll	30.1	ATM CCND1 CD5 MME SOX11 TP53
15	bladder cancer	30.0	CCND1 EZH2 MDM2 MYC TP53
16	leukemia, chronic lymphocytic	30.0	ATM BCL2 BCL6 CCND1 CCND2 CCND3
17	prostate cancer	29.7	BCL2 CCND1 EZH2 MCL1 MDM2 MTOR
18	colorectal cancer	29.4	ATM BCL2 CCND1 CCND2 MCL1 MDM2
19	lymphoma, non-hodgkin, familial	29.4	ATM BCL2 BCL6 CCND1 CCND2 CCND3
20	leukemia, acute myeloid	29.3	CD19 CD5 EZH2 MCL1 MDM2 MME
21	lymphoma, small cleaved-cell, diffuse	10.7	BCL2 CCND1
22	diffuse large b-cell lymphoma of the central nervous system	10.7	BCL2 MYC
23	ring chromosome 7	10.7	MDM2 TP53
24	synchronous bilateral breast carcinoma	10.7	ATM CCND1 TP53
25	hidradenocarcinoma	10.7	BCL2 CCND1 TP53
26	keratocystic odontogenic tumor	10.7	BCL2 CCND1 TP53
27	ectopic thymus	10.7	BCL2 CD5
28	actinic cheilitis	10.6	MDM2 TP53
29	hemimegalencephaly	10.6	CCND1 MTOR MYC
30	suppressor of tumorigenicity 3	10.6	BCL2 MYC TP53
31	pancreatic neuroendocrine tumor	10.6	ATM MTOR
32	myxosarcoma	10.6	ATM MDM2 TP53
33	focal cortical dysplasia, type ii	10.6	BCL2 MTOR TP53
34	soft tissue sarcoma	10.6	BCL2 MDM2 TP53
35	splenic diffuse red pulp small b-cell lymphoma	10.6	CCND3 TP53
36	estrogen-receptor positive breast cancer	10.6	CCND1 MTOR TP53
37	bile duct carcinoma	10.6	CCND1 MYC TP53
38	tracheal lymphoma	10.6	CD5 MME
39	male reproductive organ cancer	10.6	CCND1 MYC TP53
40	inflammatory myofibroblastic tumor	10.6	CCND1 MDM2 TP53
41	female reproductive organ cancer	10.6	CCND1 MYC TP53
42	richter's syndrome	10.6	ATM CD5 MYC TP53
43	li-fraumeni syndrome	10.6	ATM BCL2 MDM2 TP53
44	tongue cancer	10.6	BMI1 CCND1 TP53
45	cervical carcinosarcoma	10.6	BCL2 MME TP53
46	nodal marginal zone b-cell lymphoma	10.6	BCL2 BCL6
47	adult t-cell leukemia	10.5	CCND2 PMAIP1 TP53
48	oral squamous cell carcinoma	10.5	CCND1 MDM2 MYC TP53
49	dendritic cell thymoma	10.5	BCL2 CD5
50	reproductive organ cancer	10.5	CCND1 MYC TP53

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:

Sources

Symptoms & Phenotypes for Mantle Cell Lymphoma

Human phenotypes related to Mantle Cell Lymphoma:

⁵⁵ ³¹ (show all 9)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	splenomegaly ⁵⁵ ³¹	frequent (33%)	Frequent (79-30%)	HP:0001744
2	weight loss ⁵⁵ ³¹	frequent (33%)	Frequent (79-30%)	HP:0001824
3	anorexia ⁵⁵ ³¹	frequent (33%)	Frequent (79-30%)	HP:0002039
4	lymphadenopathy ⁵⁵ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0002716
5	abnormality of bone marrow cell morphology ⁵⁵ ³¹	frequent (33%)	Frequent (79-30%)	HP:0005561
6	abnormality of the gastrointestinal tract ⁵⁵ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0011024
7	fatigue ⁵⁵ ³¹	frequent (33%)	Frequent (79-30%)	HP:0012378
8	fever ⁵⁵ ³¹	frequent (33%)	Frequent (79-30%)	HP:0001945
9	b-cell lymphoma ⁵⁵ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0012191

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased cell death HMECs cells	GR00103-A-0	9.63	BCL6 BMI1 CCND2 MDM2 MYC TP53
2	Increased viability with MLN4924 (a NAE inhibitor)	GR00250-A-3	9.43	ATM BCL2 MCL1 MDM2 PMAIP1 TP53
3	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.36	ATM BCL2 MCL1 TP53
4	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.36	ATM BCL2 BTK CCND1 MCL1 MYC

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

⁴³ (show all 17)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	10.38	CD19 CCND2 CD5 CCND3 EZH2 BCL2
2	cardiovascular system	MP:0005385	10.37	CCND3 EZH2 CD19 CCND2 BCL2 CCND1
3	cellular	MP:0005384	10.36	CCND1 CD19 BTK BCL2 BCL6 ATM
4	immune system	MP:0005387	10.36	CD19 CCND2 CD5 CCND3 EZH2 BCL2
5	homeostasis/metabolism	MP:0005376	10.33	CCND3 EZH2 CCND1 CD19 CCND2 BTK
6	endocrine/exocrine gland	MP:0005379	10.32	EZH2 CCND2 CCND3 BCL2 CCND1 BCL6
7	behavior/neurological	MP:0005386	10.31	CCND3 CCND1 CD19 CCND2 BCL2 ATM
8	growth/size/body region	MP:0005378	10.31	CCND3 CCND1 CD19 BTK BCL2 BCL6
9	integument	MP:0010771	10.22	CD19 CD5 EZH2 BTK BCL2 CCND1
10	mortality/aging	MP:0010768	10.2	CCND3 CCND1 CD19 CCND2 BTK BCL2
11	embryo	MP:0005380	10.18	BCL2 ATM MTOR MDM2 EZH2 MCL1
12	digestive/alimentary	MP:0005381	10.14	CCND1 CD19 BTK BCL2 MDM2 SOX11
13	liver/biliary system	MP:0005370	9.97	CCND3 CD19 CCND2 BCL6 MDM2 MME
14	neoplasm	MP:0002006	9.96	EZH2 CD19 CCND3 BTK BCL2 CCND1
15	nervous system	MP:0003631	9.93	CCND1 CD19 CCND2 CD5 BCL2 ATM
16	normal	MP:0002873	9.73	CCND3 EZH2 CD19 CD5 CCND1 BCL6
17	reproductive system	MP:0005389	9.28	CCND1 CCND2 BCL2 BCL6 ATM MCL1

Sources

Drugs & Therapeutics for Mantle Cell Lymphoma

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁷	Company	Approval Date
1	Imbruvica ¹⁷ ⁴⁵	IBRUTINIB	Pharmacyclics	November of 2013/February 2014
FDA Label: Imbruvica Disease/s that Drug Treats:mantle cell lymphoma/chronic lymphocytic leukemia Indications and Usage: ¹⁷ IMBRUVICA is a kinase inhibitor indicated for the treatment of patients with: Mantle cell lymphoma (MCL) who have received at least one priortherapy (1.1).Accelerated approval was granted for this indication based on overallresponse rate. Continued approval for this indication may be contingentupon verification of clinical benefit in confirmatory trials. Chronic lymphocytic leukemia (CLL) who have received at least oneprior therapy (1.2). Chronic lymphocytic leukemia with 17p deletion (1.3). WaldenstrÃ¶mâs macroglobulinemia (WM) (1.4). DrugBank Targets: ¹⁵ 1. Tyrosine-protein kinase BTK Mechanism of Action: ¹⁷ Target: Bruton's tyrosine kinase (Btk) Action: selective inhibitor FDA: Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteineresidue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is asignaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTKâsrole in signaling through the B-cell surface receptors results in activation of pathways necessaryfor B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibitsmalignant B-cell proliferation and survival in vivo as well as cell migration and substrateadhesion in vitro.
2	Revlimid ¹⁷ ⁴⁵	LENALIDOMIDE	Celgene	June 2013
FDA Label: Revlimid Disease/s that Drug Treats:mantle cell lymphoma Indications and Usage: ¹⁷ REVLIMID is a thalidomide analogue indicated for the treatment of patientswith: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-riskmyelodysplastic syndromes (MDS) associated with a deletion 5qabnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressedafter two prior therapies, one of which included bortezomib (1.3).Limitations of Use: REVLIMID is not indicated and is not recommended for the treatmentof patients with chronic lymphocytic leukemia (CLL) outside ofcontrolled clinical trials (1.4). DrugBank Targets: ¹⁵ 1. Protein cereblon;2. Tumor necrosis factor ligand superfamily member 11;3. Cadherin-5;4. Prostaglandin G/H synthase 2 Mechanism of Action: ¹⁷ Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes Action: activator/inhibitor FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibitsproliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q)myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor modelsincluding multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increasednumbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-Î± and IL-6) by monocytes. In multiple myeloma cells, thecombination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
3	Velcade ¹⁷ ⁴⁵	BORTEZOMIB	Millennium Pharmaceuticals	May 2003
FDA Label: Velcade Disease/s that Drug Treats:Multiple Myeloma Indications and Usage: ¹⁷ VELCADE is a proteasome inhibitor indicated for: treatment of patients with multiple myeloma (1.1) treatment of patients with mantle cell lymphoma (1.2) DrugBank Targets: ¹⁵ 1. 26S proteasome non-ATPase regulatory subunit 2;2. 26S proteasome non-ATPase regulatory subunit 1;3. Proteasome subunit beta type-1;4. Proteasome subunit beta type-5;5. Proteasome subunit beta type-2 Mechanism of Action: ¹⁷ Target: 26S proteasome Action: reversible inhibitor of chymotrypsin-like activity FDA: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammaliancells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitinproteasomepathway plays an essential role in regulating the intracellular concentration of specific proteins,thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targetedproteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostaticmechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety ofcancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models,including multiple myeloma.

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 497)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

50-18-0, 6055-19-2

2907

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

135968-09-1

Thiotepa

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1

52-24-4

5453

Cisplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

Cytarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

147-94-4

6253

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

50-02-2

5743

Doxorubicin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

23214-92-8

31703

Etoposide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

33419-42-0

36462

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

53-03-2

5865

rituximab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

174722-31-7

10201696

Vincristine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

2068-78-2, 57-22-7

5978

Everolimus

Approved

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

159351-69-6

6442177

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

22916-47-8

4189

Sirolimus

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

53123-88-9

46835353 6436030 5284616

Doxil

Approved June 1999

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

31703

Alkylating Agents

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Antilymphocyte Serum

Phase 4,Phase 2,Phase 3,Phase 1

Antirheumatic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Angiogenesis Inhibitors

Phase 4,Phase 3,Phase 1,Phase 2

Angiogenesis Modulating Agents

Phase 4,Phase 3,Phase 1,Phase 2

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Antibiotics, Antitubercular

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Antiemetics

Phase 4,Phase 3,Phase 1,Phase 2

Anti-Infective Agents

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Anti-Inflammatory Agents

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Antimetabolites

Phase 4,Phase 3,Phase 2,Phase 1

Antimetabolites, Antineoplastic

Phase 4,Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Antineoplastic Agents, Hormonal

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Antineoplastic Agents, Phytogenic

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Antiviral Agents

Phase 4,Phase 3,Phase 1,Phase 2

Autonomic Agents

Phase 4,Phase 3,Phase 1,Phase 2

BB 1101

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Dexamethasone acetate

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

1177-87-3

Etoposide phosphate

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Gastrointestinal Agents

Phase 4,Phase 3,Phase 1,Phase 2

glucocorticoids

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

HIV Protease Inhibitors

Phase 4,Phase 3,Phase 1,Phase 2

Hormone Antagonists

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Hormones

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 1,Phase 2

protease inhibitors

Phase 4,Phase 3,Phase 1,Phase 2

Topoisomerase Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Antifungal Agents

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Carmustine

Approved, Investigational

Phase 3,Phase 2,Phase 1

154-93-8

2578

Melphalan

Approved

Phase 3,Phase 2,Phase 1

148-82-3

460612 4053

Fludarabine

Approved

Phase 3,Phase 2,Phase 1

21679-14-1, 75607-67-9

30751

Vidarabine

Approved, Investigational

Phase 3,Phase 1,Phase 2

24356-66-9

21704 32326

Interventional clinical trials:

(show top 50) (show all 956)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma	Completed	NCT01833039	Phase 4	Ibrutinib
2	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Completed	NCT00003398	Phase 4	cyclophosphamide;thiotepa
3	EDOCH Alternating With DHAP for New Diagnosed Younger MCL	Recruiting	NCT02858804	Phase 4	Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
4	Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma	Active, not recruiting	NCT01180049	Phase 4	temsirolimus;temsirolimus
5	A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion	Not yet recruiting	NCT03190330	Phase 4	Ibrutinib 420 mg;Ibrutinib 560 mg
6	Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma	Unknown status	NCT00016887	Phase 3	carmustine;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan
7	Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma	Unknown status	NCT00641095	Phase 3	cyclophosphamide;fludarabine phosphate
8	Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL	Unknown status	NCT00209222	Phase 3	Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Cisplatinum;Ara-C;Dexamethasone;BCNU;Melphalan;Etoposide;G-CSF
9	Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain	Unknown status	NCT01316744	Phase 3	ketamine hydrochloride
10	Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia	Unknown status	NCT00445497	Phase 3	amoxicillin-clavulanate potassium;ciprofloxacin
11	Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia	Unknown status	NCT00020865	Phase 3	cefepime hydrochloride;levofloxacin
12	Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	Unknown status	NCT00003338	Phase 2, Phase 3
13	Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00003337	Phase 3
14	Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	Unknown status	NCT00002989	Phase 3	busulfan;cyclophosphamide;idarubicin;melphalan
15	Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma	Unknown status	NCT00053768	Phase 3	EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
16	Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00052936	Phase 3	CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
17	Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00028717	Phase 3	cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
18	Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma	Unknown status	NCT00003924	Phase 3
19	Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy	Completed	NCT01646021	Phase 3	Ibrutinib;Temsirolimus
20	Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma	Completed	NCT00722137	Phase 3	Rituximab 375 mg/m^2;Cyclophosphamide 750 mg/m^2;Doxorubicin 50 mg/m^2;VELCADE 1.3 mg/m^2;Prednisone 100 mg/m^2;Vincristine 1.4 mg/m^2
21	Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study	Completed	NCT00877006	Phase 3	bendamustine;rituximab;vincristine;prednisone;cyclophosphamide;doxorubicin
22	Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)	Completed	NCT01073163	Phase 3	Bendamustine;Rituximab
23	Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma	Completed	NCT00003280	Phase 3
24	Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)	Completed	NCT00117598	Phase 3	Temsirolimus (CCI-779);Temsirolimus (CCI-779);Investigator's choice
25	Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab	Completed	NCT01456351	Phase 3	Bendamustine plus Rituximab;Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
26	Mantel Cell Lymphoma Efficacy of Rituximab Maintenance	Completed	NCT00921414	Phase 3	Rituximab
27	Bendamustine Plus Rituximab Versus CHOP Plus Rituximab	Completed	NCT00991211	Phase 3	Bendamustine;Standard chemotherapy CHOP + Ritiximab
28	A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma	Completed	NCT00269113	Phase 3	rituximab [MabThera/Rituxan];Standard chemotherapy
29	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	Completed	NCT00799461	Phase 3
30	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	Completed	NCT01231412	Phase 3	Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
31	Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Completed	NCT00075478	Phase 3	Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
32	Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial	Completed	NCT00750009	Phase 3
33	American Ginseng in Treating Patients With Fatigue Caused by Cancer	Completed	NCT00719563	Phase 3	American ginseng
34	Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain	Completed	NCT00666211	Phase 3
35	Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer	Completed	NCT00661999	Phase 3	sodium ferric gluconate complex in sucrose
36	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
37	St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer	Completed	NCT00005805	Phase 3
38	Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count	Completed	NCT00003805	Phase 3	piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
39	Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter	Completed	NCT00006083	Phase 3	Fragmin
40	Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer	Completed	NCT00070382	Phase 3	darbepoetin alfa;epoetin alfa
41	Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment	Completed	NCT00008359	Phase 3	caspofungin acetate;liposomal amphotericin B
42	Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma	Completed	NCT00005590	Phase 3	levofloxacin
43	Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients	Completed	NCT00003938	Phase 3	liposomal amphotericin B
44	Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	Completed	NCT00003341	Phase 3
45	Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant	Completed	NCT00305851	Phase 3
46	Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer	Completed	NCT00265837	Phase 3
47	Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma	Completed	NCT00278421	Phase 3	cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
48	Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	Completed	NCT00278408	Phase 3	cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
49	Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation	Completed	NCT00004230	Phase 3	captopril;cyclophosphamide
50	Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation	Completed	NCT00014391	Phase 3	ribavirin

Search NIH Clinical Center for Mantle Cell Lymphoma

Inferred drug relations via UMLS ⁶⁹ / NDF-RT ⁴⁷ :

ibrutinib

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Mantle Cell Lymphoma:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies
	Hematopoietic stem cells for treatment of non-Hodgkin's lymphoma
	Peripheral blood stem cells for treatment of hematologic malignancies

Embryonic/Adult Cultured Cells Related to Mantle Cell Lymphoma:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells
	Peripheral blood-derived hematopoietic stem cells PMIDs: 21831743

Cochrane evidence based reviews: lymphoma, mantle-cell

Sources

Genetic Tests for Mantle Cell Lymphoma

Genetic tests related to Mantle Cell Lymphoma:

#	Genetic test	Affiliating Genes
1	Mantle Cell Lymphoma ²⁸

Sources

Anatomical Context for Mantle Cell Lymphoma

MalaCards organs/tissues related to Mantle Cell Lymphoma:

³⁸

B Cells, Bone, Bone Marrow, T Cells, Liver, Kidney, Lymph Node

Sources

Publications for Mantle Cell Lymphoma

Articles related to Mantle Cell Lymphoma:

(show top 50) (show all 1070)

#	Title	Authors	Year
1	Can we improve on ibrutinib in mantle cell lymphoma? ( 29396093 )	Rule S.	2018
2	Gastrointestinal involvement by mantle cell lymphoma identified by biopsy performed during endoscopy: A case report. ( 29419676 )	Zheng Q.F....Nong B.	2018
3	Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. ( 29449436 )	Arvidsson G....Wright A.P.	2018
4	Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant? ( 29415598 )	Marrero W.D....Cabanillas F.	2018
5	Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. ( 29396091 )	Jerkeman M....nbA	2018
6	Population-based study of mantle cell lymphoma: Improvements in survival only seen in younger patients. ( 29363157 )	Joshi K....Bishton M.J.	2018
7	CD40L mediated alternative NFI_B-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. ( 29367645 )	Rauert-Wunderlich H....Rosenwald A.	2018
8	Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma. ( 29392403 )	Yan X....Jin J.	2018
9	Mantle Cell Lymphoma with a Single Protruding Lesion as the Cause of Intussusception. ( 29434133 )	Matsueda K....Horii J.	2018
10	Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. ( 29390098 )	Inwards D.J....Witzig T.E.	2018
11	Commentary on: Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries. ( 29380057 )	Goungounga J.A....Giorgi R.	2018
12	Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. ( 29385883 )	Ettleson M....Marini B.L.	2018
13	Rac1 is a novel therapeutic target in mantle cell lymphoma. ( 29434202 )	Tian T....Fu K.	2018
14	Current trials for frontline therapy of mantle cell lymphoma. ( 29374487 )	Steiner R.E....Wang M.	2018
15	Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma. ( 29383700 )	Jiang H....Tao J.	2018
16	Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines. ( 29441438 )	Restelli V....Carrassa L.	2018
17	Wogonin Inhibits Growth of Mantle Cell Lymphoma Cells through Nuclear Factor-I_B Signaling Pathway. ( 29451160 )	Xu P.P....Ouyang J.	2018
18	Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. ( 28408615 )	Lee H.J....Wang M.	2017
19	Correction: ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy. ( 28373366 )		2017
20	Lacrimal gland and extensive subcutaneous tissue involvement by mantle cell lymphoma. ( 28860327 )	Khodarahmi I....Ghesani N.	2017
21	Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. ( 28404221 )	Sandoval-Sus J.D....Shah B.D.	2017
22	Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma. ( 29043141 )	Miyata K.N....Winchester J.F.	2017
23	Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients. ( 27776009 )	Hu Z....Hu S.	2017
24	Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications. ( 28115200 )	Mostaghel E.A....Gopal A.K.	2017
25	Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. ( 28040733 )	Spurgeon S.E....Smith M.R.	2017
26	Sudden Flank Pain in a Patient Receiving Ibrutinib for Mantle Cell Lymphoma. ( 28910460 )	Law Y.X.T....Lee L.S.	2017
27	Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi. ( 28082342 )	Zaja F....Fanin R.	2017
28	Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission. ( 28828884 )	El-Galaly T.C....Cheah C.Y.	2017
29	SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity. ( 28457728 )	Sabour S.	2017
30	Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. ( 28416797 )	Zhao X....Tao J.	2017
31	"Double trouble" - synchronous mantle cell lymphoma and metastatic squamous cell carcinoma in an inguinal lymph node. ( 29363922 )	Szumera-CieA8kiewicz A....Prochorec-Sobieszek M.	2017
32	The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma. ( 28905990 )	Li J....Zhu J.	2017
33	Mantle Cell Lymphoma in the Thyroid: A Rare Presentation. ( 29435379 )	Siddiqui U.M....Torres M.S.	2017
34	Case Study: Rare Case of Mantle Cell Lymphoma With Extranodal Involvement in the Foot. ( 28842094 )	Fu P....Mannan A.A.S.R.	2017
35	The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma. ( 28503306 )	Masamha C.P.	2017
36	Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. ( 28066928 )	Epperla N....Fenske T.S.	2017
37	Gastrointestinal mantle cell lymphoma with isolated mass and multiple lymphomatous polyposis: report of two cases. ( 28451951 )	Yanai S....Matsumoto T.	2017
38	SOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma. ( 28429312 )	Yang W....Qiu L.	2017
39	Orbital mantle cell lymphoma presenting as myasthenia gravis. ( 28820310 )	Karlin J....Kirzhner M.	2017
40	Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia. ( 28592433 )	Zhang H....McCarty N.	2017
41	Mantle cell lymphoma with central nervous system involvement simulating bilateral subdural hematomas. ( 28063897 )	GonzA!lez-Bonet L.G....Gaona-Morales J.	2017
42	Mantle Cell Lymphoma Presenting as a Subcutaneous Soft Tissue Mass With an Unusual Appearance. ( 28081018 )	Cherukuri A.R....DeStigter K.K.	2017
43	Expression of LEF1 in mantle cell lymphoma. ( 28038713 )	O'Malley D.P....Bellizzi A.M.	2017
44	Anchimerically Activated ProTides as Inhibitors of Cap-Dependent Translation and Inducers of Chemosensitization in Mantle Cell Lymphoma. ( 28858511 )	Okon A....Wagner C.R.	2017
45	The interaction between ATRIP and MCM complex is essential for ATRIP chromatin loading and its phosphorylation in mantle cell lymphoma cells. ( 29442041 )	Nie Y....Lang T.	2017
46	Maintenance Rituximab after High-Dose Therapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma. ( 28939452 )	Roider T....Dietrich S.	2017
47	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. ( 28953447 )	Le Gouill S....Hermine O.	2017
48	Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis. ( 28529032 )	Ma J....Xie Y.	2017
49	The BTK inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on the NF-I_B mutational status. ( 28838994 )	Vidal-Crespo A....PAcrez-GalA!n P.	2017
50	A possible new morphological variant of mantle cell lymphoma with plasma-cell type Castleman disease-like features. ( 28974340 )	Igawa T....Sato Y.	2017

Sources

Genes for Mantle Cell Lymphoma

Genes related to Mantle Cell Lymphoma (3 elite genes):

(show all 37)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Implication	PubmedIds
1	ATM	ATM Serine/Threonine Kinase	Protein Coding	812.09	Pathogenic ⁶ Causative somatic mutation ⁵⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵¹ GeneCards inferred via : Disorders Publications Functions Variants (show sections)	16956411
2	CCND1	Cyclin D1	Protein Coding	408.9	Causative somatic mutation ⁵⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵¹ GeneCards inferred via : Disorders Publications Functions (show sections)	20062012 9846986 8204893 (more) 7772515 9010577 9209645 7918073 8695815 16448697 17145584 8172819 8172823 18606985
3	IGH	Immunoglobulin Heavy Locus	Protein Coding	358.28	Causative somatic mutation ⁵⁵ GeneCards inferred via : Publications (show sections)
4	BMI1	BMI1 Proto-Oncogene, Polycomb Ring Finger	Protein Coding	30.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵¹ GeneCards inferred via : Publications (show sections)	11389032 16528373
5	EZH2	Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit	Protein Coding	30.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵¹ GeneCards inferred via : Publications (show sections)	11389032
6	BCL6	B Cell CLL/Lymphoma 6	Protein Coding	29.69	DISEASES inferred ¹⁴ Novoseek inferred ⁵¹ GeneCards inferred via : Publications (show sections)	9209651
7	BCL2	BCL2, Apoptosis Regulator	Protein Coding	28.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵¹ GeneCards inferred via : Publications (show sections)	9090492 8172819
8	SOX11	SRY-Box 11	Protein Coding	27.46	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	MDM2	MDM2 Proto-Oncogene	Protein Coding	27.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵¹ GeneCards inferred via : Publications (show sections)	17488676
10	CD5	CD5 Molecule	Protein Coding	27.12	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	BTK	Bruton Tyrosine Kinase	Protein Coding	25.27	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	TP53	Tumor Protein P53	Protein Coding	25.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	CCND2	Cyclin D2	Protein Coding	24.86	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	24.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	MME	Membrane Metalloendopeptidase	Protein Coding	24.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	24.7	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	MCL1	MCL1, BCL2 Family Apoptosis Regulator	Protein Coding	24.69	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	PMAIP1	Phorbol-12-Myristate-13-Acetate-Induced Protein 1	Protein Coding	24.46	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	CD19	CD19 Molecule	Protein Coding	24.45	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	CCND3	Cyclin D3	Protein Coding	24.19	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	CCNG1	Cyclin G1	Protein Coding	18.64	DISEASES inferred ¹⁴ Novoseek inferred ⁵¹ GeneCards inferred via : Publications (show sections)	9209645
22	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	13.85	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	13.74	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	CDK4	Cyclin Dependent Kinase 4	Protein Coding	13.7	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	CD200	CD200 Molecule	Protein Coding	13.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	BCL2L1	BCL2 Like 1	Protein Coding	13.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	CDKN1B	Cyclin Dependent Kinase Inhibitor 1B	Protein Coding	13.12	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	ROR1	Receptor Tyrosine Kinase Like Orphan Receptor 1	Protein Coding	13.08	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	MIR17HG	MiR-17-92a-1 Cluster Host Gene	RNA Gene	12.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	SETMAR	SET Domain And Mariner Transposase Fusion Gene	Protein Coding	12.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	CD40	CD40 Molecule	Protein Coding	12.57	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
32	SYK	Spleen Associated Tyrosine Kinase	Protein Coding	12.57	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
33	CD40LG	CD40 Ligand	Protein Coding	12.55	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
34	PARP1	Poly(ADP-Ribose) Polymerase 1	Protein Coding	12.55	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	CASP3	Caspase 3	Protein Coding	12.52	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	ITGAX	Integrin Subunit Alpha X	Protein Coding	12.5	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	CD74	CD74 Molecule	Protein Coding	12.4	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Mantle Cell Lymphoma

ClinVar genetic disease variations for Mantle Cell Lymphoma:

⁶

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	ATM	NM_000051.3(ATM): c.7251_7253dupGAA (p.Lys2418_Arg2419insLys)	duplication	Pathogenic	rs796051857	GRCh38	Chromosome 11, 108329182: 108329184
2	ATM	NM_000051.3(ATM): c.7268A> G (p.Glu2423Gly)	single nucleotide variant	Pathogenic	rs121434221	GRCh37	Chromosome 11, 108199926: 108199926
3	ATM	NM_000051.3(ATM): c.4081C> T (p.Gln1361Ter)	single nucleotide variant	Pathogenic	rs121434222	GRCh37	Chromosome 11, 108158414: 108158414

Cosmic variations for Mantle Cell Lymphoma:

⁹ (show top 50) (show all 319)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	Conf
1	COSM3733325	ZNF296	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.488G>A	p.G163D	7
2	COSM3733324	UBR5	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.6190G>A	p.E2064K	7
3	COSM3733267	UBR5	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.8147C>G	p.S2716*	7
4	COSM6901	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.559+1G>A	p.?	7
5	COSM44687	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.379T>C	p.S127P	7
6	COSM44972	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.831T>A	p.C277*	7
7	COSM43846	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.487T>C	p.Y163H	7
8	COSM10786	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.949C>T	p.Q317*	7
9	COSM10883	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.731G>A	p.G244D	7
10	COSM11114	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.528C>G	p.C176W	7
11	COSM10662	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.743G>A	p.R248Q	7
12	COSM11450	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.644G>T	p.S215I	7
13	COSM10758	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.659A>G	p.Y220C	7
14	COSM44309	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.440T>G	p.V147G	7
15	COSM10749	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.830G>T	p.C277F	7
16	COSM10659	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.817C>T	p.R273C	7
17	COSM43651	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.763A>T	p.I255F	7
18	COSM43826	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.706T>A	p.Y236N	7
19	COSM43814	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.587G>C	p.R196P	7
20	COSM10724	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.839G>C	p.R280T	7
21	COSM10648	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.524G>A	p.R175H	7
22	COSM10705	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.586C>T	p.R196*	7
23	COSM44467	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.497C>G	p.S166*	7
24	COSM11089	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.584T>C	p.I195T	7
25	COSM10656	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.742C>T	p.R248W	7
26	COSM44962	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.774A>T	p.E258D	7
27	COSM11123	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.838A>G	p.R280G	7
28	COSM44571	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.581T>G	p.L194R	7
29	COSM10660	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.818G>A	p.R273H	7
30	COSM10667	TP53	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.646G>A	p.V216M	7
31	COSM3733439	SMC1A	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.2398C>G	p.Q800E	7
32	COSM3733438	SMC1A	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.2400G>T	p.Q800H	7
33	COSM3733301	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.2641G>A	p.D881N	7
34	COSM3733382	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.3109A>T	p.N1037Y	7
35	COSM3733287	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.4600C>A	p.Q1534K	7
36	COSM3733280	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.3724G>T	p.E1242*	7
37	COSM3733500	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.3565C>G	p.R1189G	7
38	COSM3733331	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.2897G>A	p.R966Q	7
39	COSM3733266	SMARCA4	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.3186C>G	p.H1062Q	7
40	COSM3733321	SI	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.1126C>T	p.R376W	7
41	COSM3733285	SI	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.1825T>C	p.W609R	7
42	COSM3733430	SALL3	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.3044C>T	p.S1015F	7
43	COSM3733372	ROBO2	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.2083C>T	p.R695*	7
44	COSM3733347	ROBO2	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.964G>A	p.D322N	7
45	COSM3733293	RB1	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.2570G>T	p.R857L	7
46	COSM3733320	RB1	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.52G>A	p.A18T	7
47	COSM3733492	RB1	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.1535T>A	p.L512*	7
48	COSM171725	RB1	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.838G>T	p.E280*	7
49	COSM363436	POT1	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.803G>A	p.G268D	7
50	COSM3733311	POT1	haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma	c.131G>A	p.C44Y	7

Copy number variations for Mantle Cell Lymphoma from CNVD:

⁷ (show all 39)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	44978	10	6600000	12200000	Loss		Mantle cell lymphoma
2	49103	11	102900000	110400000	Loss	ACAT	Mantle cell lymphoma
3	49104	11	102900000	110400000	Loss	ATM	Mantle cell lymphoma
4	49105	11	102900000	110400000	Loss	CUL5	Mantle cell lymphoma
5	49106	11	102900000	110400000	Loss	FDX1	Mantle cell lymphoma
6	49107	11	102900000	110400000	Loss	NPAT	Mantle cell lymphoma
7	49108	11	102900000	110400000	Loss	RAB39	Mantle cell lymphoma
8	49703	11	110400000	112500000	Loss		Mantle cell lymphoma
9	49990	11	112500000	114500000	Loss	TMPRSS5	Mantle cell lymphoma
10	49991	11	112500000	114500000	Loss	USP28	Mantle cell lymphoma
11	49992	11	112500000	114500000	Loss	ZW10	Mantle cell lymphoma
12	54401	11	43500000	48800000	Loss	TP53I11	Mantle cell lymphoma
13	60881	11	92800000	97200000	Loss	MAML2	Mantle cell lymphoma
14	61262	11	97200000	102100000	Loss	BIRC2	Mantle cell lymphoma
15	61263	11	97200000	102100000	Loss	BIRC3	Mantle cell lymphoma
16	74176	13	101700000	104800000	Loss	BIVM	Mantle cell lymphoma
17	74177	13	101700000	104800000	Loss	ERCC5	Mantle cell lymphoma
18	74178	13	101700000	104800000	Loss	KDELC1	Mantle cell lymphoma
19	74694	13	110300000	115169878	Loss	C13orf11	Mantle cell lymphoma
20	74695	13	110300000	115169878	Loss	C13orf17	Mantle cell lymphoma
21	74696	13	110300000	115169878	Loss	CUL4A	Mantle cell lymphoma
22	74697	13	110300000	115169878	Loss	GRTP1	Mantle cell lymphoma
23	74698	3	117011831	117647068	Loss	LAMP	Mantle cell lymphoma
24	74699	13	110300000	115169878	Loss	TFDP1	Mantle cell lymphoma
25	77990	13	48877883	49056026	Deletion	RB1	Mantle cell lymphoma
26	79883	13	79000000	95000000	Copy number	miR-17-92	Mantle cell lymphoma
27	80925	13	99300000	101700000	Loss	PCCA	Mantle cell lymphoma
28	118115	17	7571720	7590868	Mutation	P53	Mantle cell lymphoma
29	141432	2	210288771	210598834	Deletion	MAP2	Mantle cell lymphoma
30	143512	2	237300000	243199373	Loss		Mantle cell lymphoma
31	170852	3	160700000	167600000	Loss	SLITRK3	Mantle cell lymphoma
32	245172	9	102600000	108200000	Loss	INVS	Mantle cell lymphoma
33	248837	9	137400000	141213431	Loss	TRAF2	Mantle cell lymphoma
34	250734	9	21967751	21994490	Deletion	CDKN2A	Mantle cell lymphoma
35	252714	9	36300000	38400000	Loss	MELK	Mantle cell lymphoma
36	254747	9	68700000	72200000	Loss	TJP2	Mantle cell lymphoma
37	256309	9	91800000	93900000	Loss	DIRAS2	Mantle cell lymphoma
38	256992	9	99300000	102600000	Loss	GPR51	Mantle cell lymphoma
39	256993	9	99300000	102600000	Loss	TBC1D2	Mantle cell lymphoma

Sources

Expression for Mantle Cell Lymphoma

Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Sources

Pathways for Mantle Cell Lymphoma

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 92)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁰ Show member pathways ILK Signaling ⁶⁰ MAPK Signaling ⁶⁰ Molecular Mechanisms of Cancer ⁶⁰ Rho Family GTPases ⁶⁰	13.91	ATM BCL2 BTK CCND1 CCND2 CCND3
2	Akt Signaling ⁶⁰ Show member pathways p38 Signaling ⁶⁰ Tec Kinases Signaling ⁶⁰	13.49	BCL2 BTK CCND1 CCND2 CCND3 MDM2
3	IL-2 Pathway ⁶⁰ Show member pathways ErbB Family Pathway ⁶⁰ ErbB2-ErbB3 Heterodimers ⁶⁰ ErbB4 Pathway ⁶⁰ Growth Hormone Signaling ⁶⁰ HMGB1 Pathway ⁶⁰ IL-4 Pathway ⁶⁰ LPS Stimulated MAPK Signaling ⁶⁰ PACAP Signaling ⁶⁰ PI3K Signaling in B-Lymphocyte ⁶⁰ Prolactin Signaling ⁶⁰ Thrombopoietin Pathway ⁶⁰ TREM1 Pathway ⁶⁰ UVC-Induced MAPK Signaling ⁶⁰	13.29	BCL2 BTK CCND1 CD19 MTOR MYC
4	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶² Colorectal cancer ³⁶ EGFR tyrosine kinase inhibitor resistance ³⁶ Glioma ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²¹ Signaling Pathways in Glioblastoma ¹ Thyroid cancer ³⁶	13.15	ATM BCL2 CCND1 CCND2 MDM2 MTOR
5	Regulation of TP53 Activity ⁶² Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶² Regulation of TP53 Activity through Methylation ⁶² Regulation of TP53 Activity through Phosphorylation ⁶² Transcriptional Regulation by TP53 ⁶²	13.04	ATM BCL6 MDM2 MTOR PMAIP1 TP53
6	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	12.97	ATM BCL2 CCND1 CCND2 CCND3 CD19
7	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ³⁶ Apoptosis ¹ Apoptosis and survival Apoptotic TNF-family pathways ²¹ Apoptosis Signaling Pathways ⁶¹ Death Receptor Signaling ⁶³	12.92	ATM BCL2 MCL1 MDM2 MYC PMAIP1
8	Pathways in cancer ³⁶	12.92	BCL2 CCND1 CCND2 CCND3 MDM2 MTOR
9	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.83	BCL2 CCND1 MTOR MYC TP53
10	Downstream signaling events of B Cell Receptor (BCR) ⁶² Show member pathways Activation of RAS in B cells ⁶² Signaling by the B Cell Receptor (BCR) ⁶²	12.8	BTK CD19 MDM2 MTOR TP53
11	Chks in Checkpoint Regulation ⁶⁰ Show member pathways DNA Repair Mechanisms ⁶⁰ Estrogen-mediated S-Phase Entry ⁶⁰ G2-M Phase Transition ⁶⁰ Parkinson's Disease Pathway ⁶⁰ SREBP Proteolysis ⁶⁰	12.74	ATM CCND1 MDM2 MYC TP53
12	Mitotic G1-G1/S phases ⁶² Show member pathways G1 to S cell cycle control ¹ G1/S Transition ⁶²	12.68	ATM CCND1 CCND2 CCND3 MDM2 MYC
13	Notch signaling pathway (KEGG) ⁶¹ Show member pathways Notch Signaling ⁶⁰ Notch signaling pathway ¹ Notch signaling pathway ³⁶ Notch Signaling Pathway ¹ Notch Signaling Pathway ¹	12.67	BCL2 BCL6 CCND1 MTOR MYC
14	Relaxin signaling pathway ³⁶ Show member pathways Endocrine resistance ³⁶ Estrogen signaling pathway ³⁶ Relaxin receptors ⁶²	12.65	BCL2 CCND1 MDM2 MTOR TP53
15	Kaposi's sarcoma-associated herpesvirus infection ³⁶ Show member pathways Hepatitis B ³⁶	12.65	BCL2 CCND1 MTOR MYC TP53
16	Wnt Signaling Pathway and Pluripotency ¹ Show member pathways Wnt signaling pathway ³⁶ Wnt Signaling Pathway ¹	12.63	CCND1 CCND2 CCND3 MYC TP53
17	DNA Damage ⁴	12.62	ATM CCND1 CCND2 CCND3 MDM2 TP53
18	Prolactin Signaling Pathway ³⁶ ¹ Show member pathways Development Prolactin receptor signaling ²¹ Leptin signaling pathway ¹	12.57	BCL2 CCND1 CCND2 MTOR MYC
19	ErbB signaling pathway ³⁶ ¹ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁵⁷ Renal cell carcinoma ³⁶ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.56	CCND1 MDM2 MTOR MYC TP53
20	Development EGFR signaling pathway ²¹ Show member pathways Development ERBB-family signaling ²¹ EGF Pathway ⁶⁰ EGFR Signaling Pathway ⁶³ ErbB receptor signaling network ¹	12.55	MDM2 MTOR MYC TP53
21	HTLV-I infection ³⁶	12.54	ATM CCND1 CCND2 CCND3 MYC TP53
22	Apoptosis Pathway ⁶⁸ Show member pathways Akt Pathway ⁶⁸ NF-kappaB Pathway ⁶⁸	12.53	ATM BCL2 MDM2 MTOR TP53
23	WNT Signaling ⁶⁰	12.51	CCND1 CCND2 CCND3 MYC TP53
24	Cell cycle ³⁶ ¹	12.48	ATM CCND1 CCND2 CCND3 MDM2 MYC
25	Cyclins and Cell Cycle Regulation ⁶⁰ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁰ Cyclin D associated events in G1 ⁶² G1 Phase ⁶² G1-S Phase Transition ⁶⁰ Phosphorylation of proteins involved in G1/S transition by active Cyclin E-Cdk2 complexes ⁶²	12.46	ATM CCND1 CCND2 CCND3 TP53
26	Jak-STAT signaling pathway (KEGG) ³⁶ Show member pathways B-Cell Development ⁶⁰ IL-7 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types ⁶¹ Interleukin-19, 20, 22, 24 ⁶² Jak/STAT Signaling Pathway ⁶¹	12.45	BCL2 CCND1 CCND2 CCND3 MCL1 MTOR
27	B cell receptor signaling pathway (KEGG) ¹ Show member pathways B cell receptor signaling pathway ³⁶ BCR signaling pathway ¹	12.44	BCL6 BTK CD19 MYC
28	Development IGF-1 receptor signaling ²¹ Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²¹ Signal transduction AKT signaling ²¹	12.44	CCND1 CCND2 CCND3 IGH MDM2 MTOR
29	Viral carcinogenesis ³⁶	12.41	CCND1 CCND2 CCND3 MDM2 PMAIP1 TP53
30	Epstein-Barr virus infection ³⁶	12.4	BCL2 CD19 MDM2 MYC TP53
31	Proteoglycans in cancer ³⁶	12.4	CCND1 MDM2 MTOR MYC TP53
32	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁶	12.4	ATM CCND1 CCND2 CCND3 MDM2 MYC
33	B Cell Receptor Signaling Pathway (sino) ⁶³ Show member pathways B Cell Receptor Signaling Pathway ⁶³	12.38	BCL6 BTK CD19 MTOR
34	p53 Signaling ⁶⁰ Show member pathways p53 Pathway ⁶³	12.36	ATM BCL2 CCND1 MDM2 TP53
35	Transcriptional misregulation in cancer ³⁶	12.35	ATM BCL6 BMI1 CCND2 MDM2 MYC
36	Apoptosis and Autophagy ⁴	12.32	BCL2 MCL1 MYC PMAIP1
37	Cell cycle Role of SCF complex in cell cycle regulation ²¹ Show member pathways Cell cycle ESR1 regulation of G1/S transition ²¹ Cell cycle Regulation of G1/S transition (part 1) ²¹ Immune response MIF-JAB1 signaling ²¹	12.29	CCND1 CCND2 CCND3 MYC
38	MAPK Signaling: Mitogen Stimulation Pathway ⁶¹ Show member pathways Akt Signaling Pathway ⁶¹	12.28	BCL2 CCND1 CCND2 CCND3 MDM2 MTOR
39	Colorectal Cancer Metastasis ⁶⁰	12.26	CCND1 CCND2 MYC TP53
40	Chronic myeloid leukemia ³⁶ Show member pathways Pancreatic cancer ³⁶	12.26	CCND1 MDM2 MTOR MYC TP53
41	Hippo signaling pathway ³⁶	12.22	CCND1 CCND2 CCND3 MYC
42	Integrated Breast Cancer Pathway ¹	12.21	ATM BCL2 CCND1 MDM2 MTOR MYC
43	FoxO signaling pathway ³⁶ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12.2	ATM BCL6 CCND1 CCND2 MDM2
44	Direct p53 effectors ¹	12.19	BCL2 BCL6 MCL1 MDM2 PMAIP1 TP53
45	Cellular senescence (KEGG) ³⁶	12.17	ATM CCND1 CCND2 CCND3 MDM2 MTOR
46	MicroRNAs in cancer ³⁶	12.17	ATM BCL2 BMI1 CCND1 CCND2 EZH2
47	IL-2 Signaling Pathway ¹ Show member pathways IL2-mediated signaling events ¹ IL-5 Signaling Pathway ¹	12.15	BCL2 BTK CCND2 MYC
48	SMAD Signaling Network ⁶⁰	12.13	ATM BCL2 MDM2 TP53
49	Thyroid hormone signaling pathway ³⁶	12.11	CCND1 MDM2 MTOR MYC TP53
50	Interleukin-4 and 13 signaling ⁶²	12.1	BCL2 BCL6 CCND1 MCL1 MYC TP53

Sources

GO Terms for Mantle Cell Lymphoma

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mitochondrial outer membrane	GO:0005741	9.62	BCL2 MCL1 MTOR PMAIP1
2	nucleoplasm	GO:0005654	9.44	ATM BCL2 BCL6 BMI1 CCND1 CCND2
3	cyclin-dependent protein kinase holoenzyme complex	GO:0000307	9.13	CCND1 CCND2 CCND3
4	cytoplasm	GO:0005737	10.13	ATM BCL2 BMI1 BTK CCND1 CCND2
5	nucleus	GO:0005634	10.06	ATM BCL2 BCL6 BMI1 BTK CCND1

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of cell proliferation	GO:0042127	9.98	BCL6 BTK CCND3 EZH2
2	negative regulation of gene expression	GO:0010629	9.97	EZH2 MDM2 MYC SOX11
3	negative regulation of apoptotic process	GO:0043066	9.95	BCL2 BCL6 CCND2 MCL1 MDM2 MYC
4	positive regulation of protein phosphorylation	GO:0001934	9.94	CCND1 CCND2 CCND3 MTOR
5	cell cycle arrest	GO:0007050	9.93	ATM MTOR MYC TP53
6	B cell receptor signaling pathway	GO:0050853	9.89	BCL2 BTK CD19
7	regulation of gene expression	GO:0010468	9.88	BCL2 BMI1 EZH2 MDM2 MYC
8	post-embryonic development	GO:0009791	9.87	ATM BCL2 MTOR
9	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	9.85	ATM MDM2 TP53
10	regulation of apoptotic process	GO:0042981	9.85	ATM BCL2 BCL6 MCL1 PMAIP1 TP53
11	response to cytokine	GO:0034097	9.84	BCL2 MCL1 TP53
12	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.82	ATM BCL2 MCL1
13	negative regulation of autophagy	GO:0010507	9.81	BCL2 MCL1 MTOR
14	cellular response to DNA damage stimulus	GO:0006974	9.8	ATM BCL2 BCL6 CCND1 MYC PMAIP1
15	ovarian follicle development	GO:0001541	9.79	ATM BCL2 MYC
16	cellular response to glucose starvation	GO:0042149	9.79	BCL2 PMAIP1 TP53
17	cellular response to organic substance	GO:0071310	9.78	BCL2 CCND1 MDM2
18	response to steroid hormone	GO:0048545	9.77	BCL2 CCND1 MDM2
19	liver regeneration	GO:0097421	9.77	CCND1 EZH2 MYC
20	positive regulation of intrinsic apoptotic signaling pathway	GO:2001244	9.75	BCL2 PMAIP1 TP53
21	response to gamma radiation	GO:0010332	9.73	BCL2 MYC TP53
22	positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway	GO:1900740	9.72	BCL2 PMAIP1 TP53
23	regulation of cell cycle	GO:0051726	9.72	ATM BCL2 CCND1 CCND2 CCND3
24	determination of adult lifespan	GO:0008340	9.71	ATM TP53
25	response to magnesium ion	GO:0032026	9.71	CCND1 MDM2
26	cell aging	GO:0007569	9.71	BCL2 MTOR TP53
27	growth	GO:0040007	9.7	BCL2 MTOR
28	oocyte development	GO:0048599	9.7	ATM BCL2
29	positive regulation of glial cell proliferation	GO:0060252	9.7	MTOR MYC
30	cellular response to gamma radiation	GO:0071480	9.7	ATM MDM2 TP53
31	response to UV-B	GO:0010224	9.69	BCL2 TP53
32	positive regulation of DNA damage response, signal transduction by p53 class mediator	GO:0043517	9.69	ATM PMAIP1
33	positive regulation of response to DNA damage stimulus	GO:2001022	9.69	ATM MYC
34	positive regulation of cyclin-dependent protein serine/threonine kinase activity	GO:0045737	9.69	CCND1 CCND2 CCND3
35	positive regulation of histone deacetylation	GO:0031065	9.68	BCL6 TP53
36	cellular response to X-ray	GO:0071481	9.68	ATM CCND2
37	mitotic G1 DNA damage checkpoint	GO:0031571	9.68	CCND1 TP53
38	response to iron ion	GO:0010039	9.67	BCL2 CCND1 MDM2
39	re-entry into mitotic cell cycle	GO:0000320	9.65	CCND1 MYC
40	regulation of mitochondrial membrane permeability	GO:0046902	9.63	BCL2 PMAIP1 TP53
41	positive regulation of neuron maturation	GO:0014042	9.62	BCL2 MTOR
42	replicative senescence	GO:0090399	9.61	ATM MME TP53
43	negative regulation of transcription by RNA polymerase II	GO:0000122	9.61	BCL6 BMI1 CCND1 CCND3 EZH2 MDM2
44	cellular response to actinomycin D	GO:0072717	9.57	MDM2 TP53
45	positive regulation of cell cycle	GO:0045787	9.46	CCND1 MDM2 MYC TP53
46	cellular response to hypoxia	GO:0071456	9.1	BCL2 MDM2 MTOR MYC PMAIP1 TP53
47	apoptotic process	GO:0006915	10.14	ATM BCL2 BTK MCL1 PMAIP1 TP53
48	positive regulation of gene expression	GO:0010628	10.06	MDM2 MTOR MYC SOX11 TP53
49	positive regulation of cell proliferation	GO:0008284	10.06	BCL2 CCND1 CCND2 MDM2 MYC SOX11
50	cell proliferation	GO:0008283	10.05	BCL2 CD5 MYC SOX11 TP53

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	9.58	ATM BCL2 BCL6 BMI1 BTK CCND1
2	protein kinase binding	GO:0019901	9.55	CCND1 CCND2 CCND3 MTOR TP53
3	BH3 domain binding	GO:0051434	8.96	BCL2 MCL1

Sources

Sources for Mantle Cell Lymphoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ ExPASy

¹⁷ FDA Approved Drugs

¹⁸ FMA

¹⁹ GeneAnalytics

²⁰ GeneCards

²¹ GeneGo (Thomson Reuters)

²² GeneHancer via GeneCards

²³ GeneReviews

²⁴ Genetics Home Reference

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HGMD

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ MalaCards

³⁹ MedGen

⁴⁰ MedlinePlus

⁴¹ MeSH

⁴² MESH via Orphanet

⁴³ MGI

⁴⁴ NCBI Bookshelf

⁴⁵ NCI

⁴⁶ NCIt

⁴⁷ NDF-RT

⁴⁸ NIH Clinical Center

⁴⁹ NIH Rare Diseases

⁵⁰ NINDS

⁵¹ Novoseek

⁵² Novus Biologicals

⁵³ OMIM

⁵⁴ OMIM via Orphanet

⁵⁵ Orphanet

⁵⁶ PathCards

⁵⁷ PharmGKB

⁵⁸ PubMed

⁵⁹ PubMed Health

⁶⁰ QIAGEN

⁶¹ R&D Systems

⁶² Reactome

⁶³ Sino Biological

⁶⁴ SNOMED-CT

⁶⁵ SNOMED-CT via HPO

⁶⁶ SNOMED-CT via Orphanet

⁶⁷ TGDB

⁶⁸ Tocris

⁶⁹ UMLS

⁷⁰ UMLS via Orphanet

⁷¹ UniProtKB/Swiss-Prot

⁷² Wikipedia

Mantle Cell Lymphoma

Aliases & Classifications for Mantle Cell Lymphoma

MalaCards integrated aliases for Mantle Cell Lymphoma:

Characteristics:

Orphanet epidemiological data:

Classifications:

External Ids:

Summaries for Mantle Cell Lymphoma

Related Diseases for Mantle Cell Lymphoma

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:

Symptoms & Phenotypes for Mantle Cell Lymphoma

Human phenotypes related to Mantle Cell Lymphoma:

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

Drugs & Therapeutics for Mantle Cell Lymphoma

FDA approved drugs:

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 69 / NDF-RT 47 :

Cell-based therapeutics:

Cochrane evidence based reviews: lymphoma, mantle-cell

Genetic Tests for Mantle Cell Lymphoma

Genetic tests related to Mantle Cell Lymphoma:

Anatomical Context for Mantle Cell Lymphoma

MalaCards organs/tissues related to Mantle Cell Lymphoma:

Publications for Mantle Cell Lymphoma

Articles related to Mantle Cell Lymphoma:

Genes for Mantle Cell Lymphoma

Genes related to Mantle Cell Lymphoma (3 elite genes):

Variations for Mantle Cell Lymphoma

ClinVar genetic disease variations for Mantle Cell Lymphoma:

Cosmic variations for Mantle Cell Lymphoma:

Copy number variations for Mantle Cell Lymphoma from CNVD:

Expression for Mantle Cell Lymphoma

Pathways for Mantle Cell Lymphoma

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

GO Terms for Mantle Cell Lymphoma

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

Sources for Mantle Cell Lymphoma

Inferred drug relations via UMLS ⁶⁹ / NDF-RT ⁴⁷ :